WO2023043219A1 - 아토피 피부염 예방 또는 치료용 겔 조성물 - Google Patents
아토피 피부염 예방 또는 치료용 겔 조성물 Download PDFInfo
- Publication number
- WO2023043219A1 WO2023043219A1 PCT/KR2022/013781 KR2022013781W WO2023043219A1 WO 2023043219 A1 WO2023043219 A1 WO 2023043219A1 KR 2022013781 W KR2022013781 W KR 2022013781W WO 2023043219 A1 WO2023043219 A1 WO 2023043219A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- atopic dermatitis
- gel composition
- gel
- polysorbate
- derivative
- Prior art date
Links
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 131
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 131
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 238000011282 treatment Methods 0.000 title abstract description 44
- 230000002265 prevention Effects 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract description 49
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 claims abstract description 43
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 29
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 29
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 29
- 229920001213 Polysorbate 20 Polymers 0.000 claims abstract description 25
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims abstract description 25
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims abstract description 25
- 229940068977 polysorbate 20 Drugs 0.000 claims abstract description 25
- 239000004094 surface-active agent Substances 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 23
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims abstract description 23
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 23
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 23
- 229940068968 polysorbate 80 Drugs 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 229910052708 sodium Inorganic materials 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 11
- 239000003755 preservative agent Substances 0.000 claims description 8
- 230000002335 preservative effect Effects 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 31
- 239000003814 drug Substances 0.000 abstract description 15
- 229940124597 therapeutic agent Drugs 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 206010003645 Atopy Diseases 0.000 abstract description 6
- 238000009472 formulation Methods 0.000 abstract description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 25
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 21
- 238000010171 animal model Methods 0.000 description 19
- 238000011156 evaluation Methods 0.000 description 19
- 230000002500 effect on skin Effects 0.000 description 17
- 230000001953 sensory effect Effects 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 10
- 239000002674 ointment Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 238000012790 confirmation Methods 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 5
- USZAGAREISWJDP-UHFFFAOYSA-N crisaborole Chemical compound C=1C=C2B(O)OCC2=CC=1OC1=CC=C(C#N)C=C1 USZAGAREISWJDP-UHFFFAOYSA-N 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229940112971 protopic Drugs 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- 239000004012 Tofacitinib Substances 0.000 description 3
- 238000005299 abrasion Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 229950008199 crisaborole Drugs 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229960001967 tacrolimus Drugs 0.000 description 3
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical group C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 3
- 229960001350 tofacitinib Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002882 calcipotriol Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- KASDHRXLYQOAKZ-XDSKOBMDSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- COPBKCYMXSUALT-UHFFFAOYSA-N 3h-1,3-oxazol-2-one Chemical compound O=C1NC=CO1.O=C1NC=CO1 COPBKCYMXSUALT-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039807 Secondary adrenocortical insufficiency Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 244000022782 cocaer Species 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 229940020485 elidel Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940045946 sodium taurodeoxycholate Drugs 0.000 description 1
- YXHRQQJFKOHLAP-FVCKGWAHSA-M sodium;2-[[(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 YXHRQQJFKOHLAP-FVCKGWAHSA-M 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention contains taurodeoxycholic acid, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient, and hyaluronic acid, a derivative thereof, or a pharmaceutically acceptable salt thereof;
- polysorbate 20 or polysorbate 80 relates to a gel composition containing a surfactant, its use for preventing, treating or improving atopic dermatitis, and its preparation method.
- Atopic diseases include asthma, allergic rhinitis, and allergic conjunctivitis in addition to atopic dermatitis.
- asthma allergic rhinitis
- allergic conjunctivitis in addition to atopic dermatitis.
- the incidence of atopic dermatitis is rapidly increasing worldwide due to the increase in environmental pollutants, and the prevalence of atopic dermatitis reaches 20% of the total population.
- Patients with atopic dermatitis suffer from reduced quality of life due to restrictions in their daily lives, and socially, the economic burden of treatment is increasing. Therefore, there is an urgent need for atopic treatment management measures.
- Atopic dermatitis is a recurrent chronic skin disease accompanied by severe itching that usually starts in infancy or childhood, and is a very common skin disease accompanied by a family history. Symptoms begin in infancy and infancy, especially around the age of 2 months, of which about 50% occur before the age of 2 years, most of which appear before the age of 5 years, whereas first symptoms appear in adults are very rare. . In some patients, symptoms are alleviated or cured spontaneously with growth, and more than half of patients with infancy symptoms improve before the age of 2 years. The shape and distribution of skin lesions are characteristic, accompanied by pruritus (pruritus), dry skin, and characteristic eczema.
- Atopy usually involves an allergic reaction.
- atopic dermatitis is not only a skin disease, but also a signal of an allergic march, such as allergic asthma and rhinitis.
- a suitable treatment drug that can cure it completely has not been developed.
- antihistamines, steroids, and immunomodulators are used as treatments for atopic dermatitis.
- Anti-inflammatory analgesics and steroid-based immunosuppressants are mainly used to alleviate inflammation and immune response.
- Elidel (pimecrolimus) cream and Protopic (tacrolimus, FK506) ointment which are non-steroidal immunomodulatory agents, were developed as agents that can replace steroid ointments, and when applied for a long time, there are no side effects seen with existing steroid ointments, It is often used for sensitive skin such as the neck and has grown rapidly to 30% of the entire atopic dermatitis market.
- the risk of cancer induction of calcineurin inhibitors has been raised, and sales are declining as only low concentration use is recognized for patients under the age of 16, and low concentration use is not recognized for children under 2 years of age. .
- the inventors of the present invention contain taurodeoxycholic acid, a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient, and hyaluronic acid, a derivative thereof or a pharmaceutically acceptable salt thereof and polysorbate 20 or polysorbate It was confirmed that the gel composition containing the surfactant of Bait 80 has a significant effect on the treatment of atopic dermatitis and also shows a significantly superior effect compared to conventional formulations, and the composition is a composition for preventing, treating or improving atopic dermatitis. By revealing that it can be used as, the present invention was completed.
- An object of the present invention is to contain taurodeoxycholic acid, a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient, hyaluronic acid, a derivative thereof or a pharmaceutically acceptable salt thereof, and polysorbate 20 or polysorbate 20 It is to provide a gel composition containing a surfactant, which is sorbate 80, and a preventive or therapeutic agent for atopic dermatitis comprising the same.
- Another object of the present invention is to provide a method for preventing, improving or treating atopic dermatitis comprising administering the gel composition to a subject.
- Another object of the present invention is to provide a use of the gel composition for use as a pharmaceutical composition for preventing or treating atopic dermatitis.
- Another object of the present invention is to provide the use of the gel composition for use as a cosmetic composition for preventing or improving atopic dermatitis.
- the present invention as an active ingredient, taurodeoxycholic acid, a derivative thereof or a pharmaceutically acceptable salt thereof; hyaluronic acid, a derivative thereof or a pharmaceutically acceptable salt thereof; and a surfactant that is polysorbate 20 or polysorbate 80.
- the gel composition can be used as a composition for preventing or treating atopic dermatitis.
- the gel composition can be used as a cosmetic composition for preventing or improving atopic dermatitis.
- the present invention provides a method for preventing or improving atopic dermatitis, comprising administering the gel composition to a subject.
- the present invention provides a method for treating atopic dermatitis, comprising administering the gel composition to a subject.
- the present invention provides the use of the gel composition for use as a pharmaceutical composition for preventing or treating atopic dermatitis.
- the present invention provides the use of the gel composition for use as a cosmetic composition for preventing or improving atopic dermatitis.
- the gel composition according to the present invention has a high therapeutic effect with fewer side effects than conventional atopic dermatitis treatment agents, and is also effective as a composition for preventing, treating or improving atopic dermatitis.
- 1 is a diagram showing the injection time of DNCB for inducing atopic dermatitis in mice and the injection time of 0.5% HY209_HA gel and 5% HY209_PEG gel for treatment of atopic dermatitis.
- Figure 2 is a diagram showing atopic dermatitis-induced sites in mice treated with various therapeutic agents including 0.5% HY209_HA gel and 5% HY209_PEG gel after induction of atopic dermatitis with DNCB.
- Figure 3 is a graph showing the sensory evaluation results of mice treated with various therapeutic agents including 0.5% HY209_HA gel and 5% HY209_PEG gel after atopic dermatitis was induced with DNCB.
- Figure 4 is a graph showing the various cytokine inhibitory abilities of mice treated with various therapeutic agents including 0.5% HY209_HA gel and 5% HY209_PEG gel after atopic dermatitis was induced with DNCB.
- Figure 5 is a diagram showing a comparison of the epidermis and dermis of mice treated with various treatments including 0.5% HY209_HA gel and 5% HY209_PEG gel after atopic dermatitis was induced with DNCB.
- Figure 6 is a graph showing the epithelial thickness measurement results of mice treated with various treatments including 0.5% HY209_HA gel and 5% HY209_PEG gel after atopic dermatitis was induced with DNCB.
- Figure 7 is a graph showing the results of measuring the thickness of the dermis of mice treated with various treatments including 0.5% HY209_HA gel and 5% HY209_PEG gel after atopic dermatitis was induced with DNCB.
- Figure 8 is a graph showing the results of measuring the spleen weight of mice treated with various treatments including 0.5% HY209_HA gel and 5% HY209_PEG gel after atopic dermatitis was induced with DNCB.
- FIG. 9 is a diagram showing the injection time of MC903 for inducing atopic dermatitis in mice and the injection time of 0.5% HY209_HA gel for atopic dermatitis treatment.
- FIG. 10 is a diagram showing atopic dermatitis-induced sites in mice treated with various therapeutic agents including 0.5% HY209_HA gel after induction of atopic dermatitis with MC903, and a graph showing sensory evaluation results and ear thickness.
- FIG. 11 is a diagram showing comparison of the epidermis and dermis of mice treated with various therapeutic agents including 0.5% HY209_HA gel after atopic dermatitis was induced with MC903, and a graph showing epidermal and dermal thickness measurement results.
- FIG. 12 is a diagram showing the injection time of oxazolone for inducing atopic dermatitis in mice and the injection time of 0.5% HY209_HA gel for atopic dermatitis treatment.
- FIG. 13 is a diagram showing atopic dermatitis-induced sites in mice treated with various therapeutic agents including 0.5% HY209_HA gel after induction of atopic dermatitis with oxazolone, and a graph showing sensory evaluation results and ear thickness.
- FIG. 14 is a graph showing the comparison of the epidermis and dermis of mice treated with various therapeutic agents including 0.5% HY209_HA gel after induction of atopic dermatitis with oxazolone, and the results of epidermal and dermal thickness measurements.
- the present invention relates to taurodeoxycholic acid, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient;
- a gel composition containing a surfactant that is polysorbate 20 or polysorbate 80 is provided.
- the present invention relates to taurodeoxycholic acid, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient for use as a pharmaceutical composition for preventing or treating atopic dermatitis;
- the taurodeoxycholic acid may be sodium taurodeoxycholic acid, but is not limited thereto.
- taurodeoxycholic acid, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient is 0.01 to 3 w/v% based on the total gel composition; Specifically, 0.01 to 1 w / v%; more specifically 0.02 to 0.5 w/v%; More specifically, it may be contained in 0.05 to 0.1 w / v%.
- the hyaluronic acid, a derivative thereof, or a pharmaceutically acceptable salt thereof may be sodium hyaluronic acid.
- the hyaluronic acid, a derivative thereof or a pharmaceutically acceptable salt thereof is 0.1 to 2 w / v% based on the total gel composition; Specifically 0.1 to 2 w / v%; 0.5 to 1.5 w/v%; More specifically, it may be contained at 1 w/v%.
- the polysorbate 20 or polysorbate 80 surfactant is 0.01 to 1 w / v% based on the total gel composition; Specifically 0.02 to 0.5 w / v%; more specifically 0.03 to 0.1 w/v%; More specifically, it may be contained at 0.05 w/v%.
- polysorbate 20 may be used as a surfactant.
- the gel composition may further include a preservative.
- methyl paraoxybenzoate may be used as the preservative.
- the preservative in the present invention based on the total gel composition 0.05 to 1 w / v%; Specifically 0.1 to 0.5 w / v%; More specifically, it may be contained at 0.2 w/v%.
- the gel composition may further contain additives such as a stabilizer, a wetting agent and/or an emulsifying agent, a solubilizing agent, a solvent, a salt and/or a buffer for adjusting osmotic pressure, and the like, but is not limited thereto.
- additives such as a stabilizer, a wetting agent and/or an emulsifying agent, a solubilizing agent, a solvent, a salt and/or a buffer for adjusting osmotic pressure, and the like, but is not limited thereto.
- the gel composition may be a pharmaceutical composition for preventing or treating atopic dermatitis.
- the gel composition may be a cosmetic composition for preventing or improving atopic dermatitis.
- the gel composition may be an animal gel composition for preventing, improving or treating atopic dermatitis.
- the dosage of the gel composition containing taurodeoxycholic acid, a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient is determined by various factors, such as the effectiveness and duration of action of the active ingredient, the mode of administration, It may vary depending on individual conditions such as sex, age, body weight of the warm-blooded animal, and the severity of other diseases.
- a specific administration route and dosage may be selected by a doctor/veterinarian in charge according to conditions such as the characteristics of the subject to be administered, that is, age, weight, disease state, and physical condition.
- the taurodeoxycholic acid may be sodium taurodeoxycholic acid, and the amount of taurodeoxycholic acid, a derivative thereof or a pharmaceutically acceptable salt thereof, based on the total gel composition, is 3 w/v%; Specifically, 0.01 to 1 w / v%; more specifically 0.02 to 0.5 w/v%; More specifically, it may be contained in 0.05 to 0.1 w / v%.
- the hyaluronic acid, a derivative thereof, or a pharmaceutically acceptable salt thereof may be sodium hyaluronic acid, and the hyaluronic acid, a derivative thereof, or a pharmaceutically acceptable salt thereof, based on the total gel composition, is 0.1 to 2 w/v%; Specifically 0.1 to 2 w / v%; 0.5 to 1.5 w/v%; More specifically, it may be contained at 1 w/v%.
- the polysorbate 20 or polysorbate 80 surfactant is 0.01 to 1 w / v% based on the total gel composition; Specifically 0.02 to 0.5 w / v%; more specifically 0.03 to 0.1 w/v%; More specifically, it may be contained at 0.05 w/v%.
- the present inventors prepared a HY209 gel containing sodium taurodeoxycholic acid and adding sodium hyaluronate, and then applied the HY209 gel to a mouse with atopic dermatitis, resulting in 0.5 It was confirmed that the % HY209 gel showed a significant effect on each symptom of atopic dermatitis, and was particularly superior to existing atopic dermatitis treatments and existing company products.
- the composition for preventing, treating, or improving atopic dermatitis containing taurodeoxycholic acid and its derivatives as an active ingredient and hyaluronic acid and its derivatives as an excipient of the present invention is targeted at atopic dermatitis-induced mice. Since it shows a significant atopic dermatitis treatment or improvement effect in skin application experiments, the composition can be usefully used as an active ingredient of a composition for preventing, treating, or improving atopic dermatitis.
- taurodeoxycholic acid As an active ingredient, taurodeoxycholic acid, a derivative thereof, or a pharmaceutically acceptable salt thereof;
- It provides a method for preventing or improving atopic dermatitis comprising administering a gel composition to a subject.
- taurodeoxycholic acid As an active ingredient, taurodeoxycholic acid, a derivative thereof, or a pharmaceutically acceptable salt thereof;
- It provides a method for treating atopic dermatitis comprising administering the gel composition to a subject.
- taurodeoxycholic acid a derivative thereof or a pharmaceutically acceptable salt thereof
- hyaluronic acid a derivative thereof or a pharmaceutically acceptable salt thereof
- a surfactant that is polysorbate 20 or polysorbate 80 a surfactant that is polysorbate 20 or polysorbate 80
- atopic dermatitis are described above.
- the description of the gel composition is the same, the specific description uses the above content.
- the gel composition prepared by the method of the present invention has fewer side effects and higher therapeutic effect than conventional atopic dermatitis treatment agents, and significantly superior effects compared to conventional formulations, the gel composition of the present invention is used to prevent atopic dermatitis, It can be usefully used for improvement or treatment.
- a 0.5% HY209 gel containing sodium taurodeoxycholate (TDCA) was prepared according to the composition shown in Table 1 below.
- Example 1 Comparative confirmation of atopic dermatitis treatment effect of 0.5% HY209_HA gel (gel) and 5% HY209_PEG gel (gel), an existing company product, in animal models through appearance observation and sensory evaluation
- atopy prepared in ⁇ Example 2> Dermatitis-induced mice were treated with DNCB group, 0.5% HY209_HA gel group, 5% HY209_PEG gel group, Dexamethasone (DEX) (Maxidex ointment, Alcon Pharmaceuticals) group, and Crisaborole (Crisabolol) (Eucry) according to the treatment method. 5 animals were randomly assigned to each of the four ointment, Pfizer Pharmaceuticals) group, Tofacitinib group, and FK506 (Tacrolimus, tacrolimus) (Protopic ointment, Leo Pharma).
- mice where atopic dermatitis was induced were performed to examine whether or not the atopic dermatitis was improved. Scores from 0 to 3 were assigned according to the severity of , abrasions and sores, scales and dryness, respectively, and the total score was calculated out of 15 points. After each blind evaluation by 3 people, the average value of each mouse individual was calculated.
- the 0.5% HY209_HA gel group and the 5% HY209_PEG gel group significantly reduced the sensory evaluation index for atopic dermatitis compared to the DNCB group.
- the 0.5% HY209_HA gel group it was confirmed that the symptoms of atopic dermatitis were significantly improved compared to the DEX group, Crisaborole group, Tofacitinib group and FK506 group used as positive control groups, and compared to the existing company product 5% HY209_PEG gel group. Even when, it was confirmed that the dose of HY209 was reduced by 10 times, but had equal or higher therapeutic effects (FIG. 2 and FIG. 3).
- Example 2 Comparative confirmation of atopic dermatitis treatment effect of 0.5% HY209_HA gel and existing company product 5% HY209_PEG gel (gel) in animal model through serum analysis
- the collected tissue samples were cut and fixed in a 10% formalin solution for 24 hours, washed with distilled water, and the fixed skin tissues were made into paraffin blocks with a thickness of 7 ⁇ m. After cutting into sections, staining with Hematoxylin and Eosin (H&E), observing using an optical microscope, epidermal and dermal thicknesses were measured using image analysis software and analyzed using analysis software.
- H&E Hematoxylin and Eosin
- Atopic dermatitis was induced by applying 1 nM of Calcipotriol (Calcipotriol, MC903) solution to the back of hairless mice twice a day for 9 days (FIG. 9).
- the 0.5% HY209_HA gel group significantly reduced the sensory evaluation index for atopic dermatitis compared to the MC903 group, and it was confirmed that the ear thickness had a therapeutic effect on atopic dermatitis symptoms (FIG. 10 ).
- the collected tissue samples were cut and fixed in a 10% formalin solution for 24 hours, washed with distilled water, and the fixed skin tissues were made into paraffin blocks with a thickness of 7 ⁇ m. After cutting into sections, staining with Hematoxylin and Eosin (H&E), observing using an optical microscope, epidermal and dermal thicknesses were measured using image analysis software and analyzed using analysis software.
- H&E Hematoxylin and Eosin
- Atopic dermatitis was induced by applying 1% oxazolone (oxazolone) solution once to the back of the hair-removed mouse, and then additionally applying 0.1% oxazolone twice a day on days 8, 10, and 15 (FIG. 12).
- mice The appearance of the atopic dermatitis-induced back of each group of mice was observed and sensory evaluation was performed to examine whether or not the atopic dermatitis was improved. Depending on the severity of edema, abrasions and sores, scaling and dryness, scores were given from 0 to 3 points, respectively, and the total score was calculated out of 15 points. After each blind evaluation by 3 people, the average value of each mouse individual was calculated.
- the 0.5% HY209_HA gel group significantly decreased the sensory evaluation index for atopic dermatitis compared to the oxazolone group, and it was confirmed that the 0.5% HY209_HA gel group had a therapeutic effect on atopic dermatitis symptoms even in the result of measuring the thickness of the ear (Fig. 13).
- the collected tissue samples were cut and fixed in a 10% formalin solution for 24 hours, washed with distilled water, and the fixed skin tissues were made into paraffin blocks with a thickness of 7 ⁇ m. After cutting into sections, staining with Hematoxylin and Eosin (H&E), observing using an optical microscope, epidermal and dermal thicknesses were measured using image analysis software and analyzed using analysis software.
- H&E Hematoxylin and Eosin
- the present invention contains taurodeoxycholic acid, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient, and hyaluronic acid, a derivative thereof, or a pharmaceutically acceptable salt thereof;
- polysorbate 20 or polysorbate 80 relates to a gel composition containing a surfactant and a composition for preventing or treating atopic dermatitis comprising the same, specifically, the composition has fewer side effects and higher treatment compared to conventional atopic dermatitis treatments It has the advantage of having a significantly superior effect compared to conventional formulations, and thus can be usefully used.
Abstract
Description
성분 | 함량(㎎) |
타우로데옥시콜린산나트륨 | 5.0 |
폴리소르베이트 80 | 0.5 |
히알루론산나트륨 | 10.0 |
파라옥시벤조산메틸 | 2.0 |
정제수 | 잔량 |
총 중량 | 1000 |
Claims (24)
- 유효성분으로서 타우로데옥시콜린산, 이의 유도체 또는 이의 약학적으로 허용되는 염;히알루론산, 이의 유도체 또는 이의 약학적으로 허용되는 염; 및폴리소르베이트 20 또는 폴리소르베이트 80인 계면활성제를 함유하는, 겔 조성물.
- 제1항에 있어서,상기 타우로데옥시콜린산은 소듐 타우로데옥시콜린산인 것을 특징으로 하는, 겔 조성물.
- 제1항에 있어서,유효성분으로서 타우로데옥시콜린산, 이의 유도체 또는 이의 약학적으로 허용되는 염은,전체 겔 조성물에 대하여 0.01 내지 3 w/v%로 함유되는 것을 특징으로 하는, 겔 조성물.
- 제1항에 있어서,유효성분으로서 타우로데옥시콜린산, 이의 유도체 또는 이의 약학적으로 허용되는 염은,전체 겔 조성물에 대하여 0.02 내지 0.5 w/v%로 함유되는 것을 특징으로 하는, 겔 조성물.
- 제1항에 있어서,유효성분으로서 타우로데옥시콜린산, 이의 유도체 또는 이의 약학적으로 허용되는 염은,전체 겔 조성물에 대하여 0.05 내지 0.1 w/v%로 함유되는 것을 특징으로 하는, 겔 조성물.
- 제1항에 있어서,상기 히알루론산, 이의 유도체 또는 이의 약학적으로 허용되는 염은 소듐 히알루론산인 것을 특징으로 하는, 겔 조성물.
- 제1항에 있어서,히알루론산, 이의 유도체 또는 이의 약학적으로 허용되는 염은,전체 겔 조성물에 대하여 0.1 내지 2 w/v%로 함유되는 것을 특징으로 하는, 겔 조성물.
- 제1항에 있어서,히알루론산, 이의 유도체 또는 이의 약학적으로 허용되는 염은,전체 겔 조성물에 대하여 0.5 내지 1.5 w/v%로 함유되는 것을 특징으로 하는, 겔 조성물.
- 제1항에 있어서,히알루론산, 이의 유도체 또는 이의 약학적으로 허용되는 염은,전체 겔 조성물에 대하여 1 w/v%로 함유되는 것을 특징으로 하는, 겔 조성물.
- 제1항에 있어서,폴리소르베이트 20 또는 폴리소르베이트 80인 계면활성제는,전체 겔 조성물에 대하여 0.01 내지 1 w/v%로 함유되는 것을 특징으로 하는, 겔 조성물.
- 제1항에 있어서,폴리소르베이트 20 또는 폴리소르베이트 80인 계면활성제는,전체 겔 조성물에 대하여 0.02 내지 0.5 w/v%로 함유되는 것을 특징으로 하는, 겔 조성물.
- 제1항에 있어서,폴리소르베이트 20 또는 폴리소르베이트 80인 계면활성제는,전체 겔 조성물에 대하여 0.03 내지 0.1 w/v%로 함유되는 것을 특징으로 하는, 겔 조성물.
- 제1항에 있어서,폴리소르베이트 20 또는 폴리소르베이트 80인 계면활성제는,전체 겔 조성물에 대하여 0.05 w/v%로 함유되는 것을 특징으로 하는, 겔 조성물.
- 제1항에 있어서,보존제를 추가로 포함하는, 겔 조성물.
- 제14항에 있어서,보존제는 파라옥시벤조산메틸인, 겔 조성물.
- 제14항에 있어서,보존제는 전체 겔 조성물에 대하여 0.05 내지 1 w/v%로 함유되는 것을 특징으로 하는, 겔 조성물.
- 제14항에 있어서,보존제는 전체 겔 조성물에 대하여 0.1 내지 0.5 w/v%로 함유되는 것을 특징으로 하는, 겔 조성물.
- 제14항에 있어서,보존제는 전체 겔 조성물에 대하여 0.2 w/v%로 함유되는 것을 특징으로 하는, 겔 조성물.
- 제1항 내지 제18항 중 어느 한 항의 겔 조성물을 포함하는,아토피 피부염 예방 또는 치료용 약학 조성물.
- 제1항 내지 제18항 중 어느 한 항의 겔 조성물을 포함하는,아토피 피부염 예방 또는 개선용 화장료 조성물.
- 유효성분으로서 타우로데옥시콜린산, 이의 유도체 또는 이의 약학적으로 허용되는 염;히알루론산, 이의 유도체 또는 이의 약학적으로 허용되는 염; 및폴리소르베이트 20 또는 폴리소르베이트 80인 계면활성제를 함유하는,겔 조성물을 개체에 투여하는 단계를 포함하는 아토피 피부염의 예방 또는 개선방법.
- 유효성분으로서 타우로데옥시콜린산, 이의 유도체 또는 이의 약학적으로 허용되는 염;히알루론산, 이의 유도체 또는 이의 약학적으로 허용되는 염; 및폴리소르베이트 20 또는 폴리소르베이트 80인 계면활성제를 함유하는,겔 조성물을 개체에 투여하는 단계를 포함하는 아토피 피부염의 치료방법.
- 아토피 피부염의 예방 또는 치료용 약학적 조성물로 사용하기 위한유효성분으로서 타우로데옥시콜린산, 이의 유도체 또는 이의 약학적으로 허용되는 염;히알루론산, 이의 유도체 또는 이의 약학적으로 허용되는 염; 및폴리소르베이트 20 또는 폴리소르베이트 80인 계면활성제를 함유하는,겔 조성물의 용도.
- 아토피 피부염의 예방 또는 개선용 화장료 조성물로 사용하기 위한유효성분으로서 타우로데옥시콜린산, 이의 유도체 또는 이의 약학적으로 허용되는 염;히알루론산, 이의 유도체 또는 이의 약학적으로 허용되는 염; 및폴리소르베이트 20 또는 폴리소르베이트 80인 계면활성제를 함유하는,겔 조성물의 용도.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280062684.0A CN117956982A (zh) | 2021-09-15 | 2022-09-15 | 一种预防或治疗特应性皮炎的凝胶组合物 |
AU2022346513A AU2022346513A1 (en) | 2021-09-15 | 2022-09-15 | Gel composition for prevention or treatment of atopic dermatitis |
CA3232028A CA3232028A1 (en) | 2021-09-15 | 2022-09-15 | Gel composition for preventing or treating atopic dermatitis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0122994 | 2021-09-15 | ||
KR1020210122994A KR20230039979A (ko) | 2021-09-15 | 2021-09-15 | 아토피 피부염 예방 또는 치료용 겔 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023043219A1 true WO2023043219A1 (ko) | 2023-03-23 |
Family
ID=85603245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/013781 WO2023043219A1 (ko) | 2021-09-15 | 2022-09-15 | 아토피 피부염 예방 또는 치료용 겔 조성물 |
Country Status (5)
Country | Link |
---|---|
KR (1) | KR20230039979A (ko) |
CN (1) | CN117956982A (ko) |
AU (1) | AU2022346513A1 (ko) |
CA (1) | CA3232028A1 (ko) |
WO (1) | WO2023043219A1 (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6258830B1 (en) * | 1994-06-07 | 2001-07-10 | Allergan Sales, Inc. | Stable gel formulation for topical treatment of skin conditions |
WO2004073614A2 (en) * | 2003-02-14 | 2004-09-02 | Combinatorx, Incorporated | Combination therapy for the treatment of immunoinflammatory disorders |
US20080306137A1 (en) * | 2006-02-20 | 2008-12-11 | Beijing Century Biocom Pharmaceutical Technology Co., Ltd. | Pharmaceutical compositions comprising docetaxel and methods for preparation thereof |
KR20170013854A (ko) * | 2014-01-29 | 2017-02-07 | 바이옴 바이오사이언스 피브이티. 엘티디. | 저항성 여드름을 위한 치료 |
US20170196895A1 (en) * | 2013-08-26 | 2017-07-13 | Shaperon Inc. | Composition comprising gpcr19 agonist as an active ingredient for preventing or treating allergic dermatitis |
WO2020186010A1 (en) * | 2019-03-12 | 2020-09-17 | Epm Group, Inc. | Cannabinoid acid ester compositions and uses thereof |
-
2021
- 2021-09-15 KR KR1020210122994A patent/KR20230039979A/ko unknown
-
2022
- 2022-09-15 WO PCT/KR2022/013781 patent/WO2023043219A1/ko active Application Filing
- 2022-09-15 CA CA3232028A patent/CA3232028A1/en active Pending
- 2022-09-15 CN CN202280062684.0A patent/CN117956982A/zh active Pending
- 2022-09-15 AU AU2022346513A patent/AU2022346513A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6258830B1 (en) * | 1994-06-07 | 2001-07-10 | Allergan Sales, Inc. | Stable gel formulation for topical treatment of skin conditions |
WO2004073614A2 (en) * | 2003-02-14 | 2004-09-02 | Combinatorx, Incorporated | Combination therapy for the treatment of immunoinflammatory disorders |
US20080306137A1 (en) * | 2006-02-20 | 2008-12-11 | Beijing Century Biocom Pharmaceutical Technology Co., Ltd. | Pharmaceutical compositions comprising docetaxel and methods for preparation thereof |
US20170196895A1 (en) * | 2013-08-26 | 2017-07-13 | Shaperon Inc. | Composition comprising gpcr19 agonist as an active ingredient for preventing or treating allergic dermatitis |
KR20170013854A (ko) * | 2014-01-29 | 2017-02-07 | 바이옴 바이오사이언스 피브이티. 엘티디. | 저항성 여드름을 위한 치료 |
WO2020186010A1 (en) * | 2019-03-12 | 2020-09-17 | Epm Group, Inc. | Cannabinoid acid ester compositions and uses thereof |
Non-Patent Citations (1)
Title |
---|
SILVA LUIS ANTÔNIO DANTAS, ANDRADE LÍGIA MARQUEZ, DE SÁ FERNANDO AUGUSTO PIRES, MARRETO RICARDO NEVES, LIMA ELIANA MARTINS, GRATIE: "Clobetasol-loaded nanostructured lipid carriers for epidermal targeting", JOURNAL OF PHARMACY AND PHARMACOLOGY : JPP, JOHN WILEY & SONS LTD, LONDON, GB, vol. 68, no. 6, 27 May 2016 (2016-05-27), GB , pages 742 - 750, XP093047757, ISSN: 0022-3573, DOI: 10.1111/jphp.12543 * |
Also Published As
Publication number | Publication date |
---|---|
CN117956982A (zh) | 2024-04-30 |
KR20230039979A (ko) | 2023-03-22 |
CA3232028A1 (en) | 2023-03-23 |
AU2022346513A1 (en) | 2024-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005300727B2 (en) | Use of Pirlindole for the treatment of diseases which are characterized by proliferation of T-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis | |
CN110139662B (zh) | 肽的抗炎用途 | |
RU2533458C2 (ru) | Композиции, содежащие берберин или его аналоги для лечения кожных заболеваний, связанных с розацеа или с покраснением лица | |
EP0738516A1 (en) | External preparation for skin protection | |
JPH07503456A (ja) | 医薬的ジペプチド組成物およびその使用法 | |
WO2012148174A2 (ko) | 탈모방지 및 발모촉진용 외용제 조성물 | |
CA2521152A1 (en) | Use of a topical medicament comprising riluzole | |
WO2021112398A1 (ko) | 비타민 c를 포함하는 조성물 | |
WO2012020989A2 (ko) | 니코틴산 아데닌 디뉴클레오티드 인산 또는 그의 유도체를 포함하는 약학적 또는 화장료 조성물 | |
WO2015030328A1 (ko) | Gpcr19 작용제를 유효성분으로 함유하는 알러지성 피부질환의 예방 또는 치료용 조성물 | |
WO2023043219A1 (ko) | 아토피 피부염 예방 또는 치료용 겔 조성물 | |
US10722492B2 (en) | Andrographolide treats progressive forms of multiple sclerosis | |
WO2014129818A1 (ko) | 당뇨병성 창상의 예방 또는 치료용 약학 조성물 | |
US20150335617A1 (en) | Methods and compositions for treating psoriasis | |
WO2020222552A1 (ko) | 6-디아조-5-옥소-l-노르루신을 포함하는 염증성 피부질환 치료용 약제학적 조성물 | |
JPH03204815A (ja) | 皮膚炎に対する治療用組成物 | |
WO2022245089A1 (ko) | 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물 | |
JPS6259219A (ja) | 外用鎮咳・去痰・鎮痛・鎮静剤 | |
Smith et al. | Eruptive collagenoma | |
WO2021125632A1 (ko) | 파에오놀 및 판테놀 또는 이들의 약학적으로 혀용가능한 염을 유효성분으로 포함하는 외용제 조성물 | |
WO2019045214A1 (ko) | 아토피피부염 예방 또는 치료용 조성물 | |
AU5100300A (en) | Use of a vitamin combination for the treatment of pruritus and non-infective disorders involving itching and/or inflammation | |
WO2018034539A1 (ko) | 리보플라빈을 포함하는 가려움증 억제 또는 완화용 조성물 | |
WO2020166773A1 (ko) | 생약추출물을 유효성분으로 포함하는 국소 지방 분해용 조성물 | |
KR20200126882A (ko) | 6-디아조-5-옥소-l-노르루신을 포함하는 염증성 피부 질환 치료용 약제학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22870303 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3232028 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022346513 Country of ref document: AU Ref document number: AU2022346513 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2022346513 Country of ref document: AU Date of ref document: 20220915 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022870303 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022870303 Country of ref document: EP Effective date: 20240415 |